Expression of ULBP on the blood cells of patients with PNH. (A) Flow cytometry revealed the expression of ULBPs 1-3 on GPI⁺ granulocytes (shaded histograms) of a patient with PNH (patient no. 1 in Table 1) but on neither his GPI^- granulocytes nor control granulocytes of a healthy volunteer. (B) Expression profiles of ULBPs were summarized in 14 PNH patients (PNH: ○, CD59⁺; •, CD59^-) and 17 healthy volunteers (Control, ▵). Arrows indicate the average of mean fluorescence intensities in each population. (C) ULBPs 1-3 were expressed on CD34⁺ BM cells (shaded histograms) of a patient with PNH (patient no. 10 in Table 1). 87% of the cells were positive for CD59. Only ULBP3 was detected on the BM cells of a healthy volunteer. Dotted lines show nonspecific background staining with isotype-matched control Ig. (D) Expression of MICA on CD59⁺ and CD59^- granulocytes (shaded histograms) of a patient with PNH (patient no. 9 in Table 1) who had granulocytes expressing membrane ULBPs. (E) Expression of ULBP2 mRNA in granulocytes of 7 patients with PNH (lanes 1-7) and 2 healthy donors (lanes 8 and 9). Lanes 1-3 show patients with PNH having granulocytes expressing membrane ULBPs; lanes 4-7, PNH patients having granulocytes lacking membrane ULBPs. M indicates 100-bp DNA ladder; lanes 1-7, patient nos. 2, 3, 4, 7, 10, 12, or 6 in Table 1; lane 10, K562 cells; and G3PDH, glyceraldehyde 3-phosphate dehydrogenase. Dotted lines in panels A, C, and D indicate nonspecific background staining with isotype-matched control Ig.